CV DEATH HAS A NEW OPPONENT
CV DEATH HAS A NEW OPPONENT

Let's Talk - Impact of SGLT2i trials in HFpEF

Document ID: PC-PH-104987

01/08/2023

Author: Boehringer Ingelheim

123,000
Views

100k 340

Related content

 
PC-PH-104987
Production date: August 2023